glp-1 drugs and dementia Could diabetes weight loss treat Alzheimer's disease? NEW STUDY: GLP-1 meds slash

It may result in additional body weight loss and greater improvements in metabolic function

136 Exogenously administered somatostatin inhibits glucagon release from islet alpha-cells and insulin release from islet beta-cells, and antibodies against somatostatin induce glucagon secretion from islet alpha-cells

There are a large number of studies that have reported the application of exendin-4, liraglutide and exenatide in the treatment of cognitive dysfunction and pathological features in AD models

As interest rises, alternative delivery systems are emerging, including transdermal supplements such as the Patchie GLP-1 Patches, which claim to mimic similar appetite-suppressing and metabolism-supporting effects through skin absorption rather than injections

Laboratory investigation typically includes comprehensive metabolic panel, magnesium level, creatine kinase (if muscle injury is suspected), and possibly vitamin D level

Introduction# Pemvidutide and survodutide are both GLP-1/glucagon dual receptor agonists being developed for obesity and metabolic-associated steatohepatitis (MASH)